China Resources Double-Crane Pharmaceutical (SHA:600062) subsidiary Hunan Xiangzhong Pharmaceutical obtained a drug registration for its sodium valproate sustained-release tablets from China's drug administrator.
Sodium valproate is used to treat epilepsy and mania, according to a Thursday filing with the Shanghai Stock Exchange.
Shares of the pharmaceutical company rose 1% in recent trade.